Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
about
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.Evaluation of a potential tigecycline-warfarin drug interaction.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Multi-drug-resistant Klebsiella pneumoniae pancreatitis: a new challenge in a serious surgical infection.Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineFrequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.Use of tigecycline in pediatric clinical practice.Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.Pharmacokinetics and pharmacodynamics of antibacterial agents.Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.Tigecycline: a critical update.In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Pharmacokinetics of tigecycline in turkeys following different routes of administration.Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals.In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period.Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation.Determination of tigecycline in human plasma by LC-MS/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia.
P2860
Q33657212-50CFDE00-6742-4A81-8411-797169A64AD5Q34309522-40FEEF52-ABA9-477E-A77F-6FE499B38FAAQ34309574-1EAC1F71-8F74-4F07-BED7-BDCB95004A9CQ34513298-357E6C17-3EFA-4B56-8444-2D67CBB6A48FQ34593514-17321C69-69BA-401E-91F4-F7D4E6EC41C4Q34803735-46B08C08-EACE-4621-8E57-B5C49E836AF7Q35026616-DBFB0C49-CBBC-426B-9D23-658E9D7EACE8Q35376617-3C152251-ACE3-4F70-AB30-7427A6E0B501Q35666608-8C3DD509-3E94-4799-8468-26B66DC6AF31Q35689185-84028E60-B691-4A77-9673-2B64CE6144ABQ35806456-A7EF915F-54E7-4B44-A0F2-38F5717C350FQ36342430-7FAAD025-B4BA-4B4C-B621-0315348568C4Q36422712-6D3C91EF-6F44-467B-82DD-B50B8C085C08Q36663656-5086037C-9CD1-4CBC-9686-5F0590AF45C4Q36757628-9AF28D98-2491-4822-8F9D-CD0735417795Q36911111-7050CE30-FBFE-4A5A-B641-34255D2EFCDDQ37115690-137BD771-47C8-4AEF-8E07-7B9EB566779CQ37233932-B7AE9D91-CD3B-431B-95C0-86D9E2A74DD0Q37247732-31CF743A-88AF-4A19-8567-A3602D39E346Q37450779-6CF41F5D-1696-49D1-8BB9-FE667552EBEBQ37940546-FC89B6C6-6953-4F4E-847A-46756B0E6661Q38100704-36AB1448-DB95-4E20-802A-AF151D977DBDQ38664871-E978CF5B-4D01-495C-80B0-B42549DD93E4Q40082835-727C21B3-7A84-46B6-B0C2-397BA6CC3A96Q40175198-536CEBCD-1CFA-4777-B74D-375E992C13DDQ40236833-920E1267-2679-4230-8D72-5E0FDC0F4CACQ40248088-F6E14DA8-0A3C-40D2-8502-73A9953B040DQ40334499-21F0D24D-8693-419A-950B-B2BC4E860EBAQ40533542-10202F61-52BC-4EE1-82B9-B113FC7D02A9Q41387743-B1B37E1F-08CF-4E9C-880E-077D4174FE7FQ42529569-B0C4A70B-F200-4AC2-98DF-9C4FFEDA3368Q46255695-3FD64A7E-4D12-4820-B84E-3F03AB345DAEQ46699478-0445F59C-AA11-465F-B472-793E64A3B34EQ47315435-AD5A1CC9-34FB-4410-81F8-35BAD155F808Q47983248-8A1E863C-1948-4B4A-8F80-30A4DA612E27
P2860
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Exposure-response analyses of ...... and skin-structure infections.
@ast
Exposure-response analyses of ...... and skin-structure infections.
@en
type
label
Exposure-response analyses of ...... and skin-structure infections.
@ast
Exposure-response analyses of ...... and skin-structure infections.
@en
prefLabel
Exposure-response analyses of ...... and skin-structure infections.
@ast
Exposure-response analyses of ...... and skin-structure infections.
@en
P2093
P2860
P356
P1476
Exposure-response analyses of ...... and skin-structure infections.
@en
P2093
A K Meagher
B B Cirincione
E J Ellis-Grosse
J A Passarell
P G Ambrose
S A Van Wart
T Babinchak
P2860
P304
P356
10.1128/AAC.01084-06
P407
P577
2007-03-12T00:00:00Z